Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2026 04:41 ET | Source: Novo Nordisk A/S

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

New results from the landmark POSEIDON real-world evidence study at EAS Congress: 2 in 5 people with CVD have CV inflammation - higher risk of heart attack
May 22, 2026 13:30 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

CHMP has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg in a single-dose pen for people living with obesity.
May 22, 2026 09:09 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

CHMP under (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® pill to reduce excess body weight
May 19, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
May 18, 2026 09:38 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
May 13, 2026 02:00 ET | Source: Novo Nordisk A/S

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Wegovy® pill showed 21.6% weight loss in early responders and improved mobility in OASIS-4 data at ECO2026.
May 12, 2026 10:49 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
May 12, 2026 06:25 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.
May 12, 2026 02:00 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity

Higher-dose Wegovy led to up to 28% weight loss, mainly from fat, with muscle preserved, new trial data show.
May 06, 2026 01:31 ET | Source: Novo Nordisk A/S

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

The strong performance of Wegovy® and continued growth in International Operations have led us to raise our 2026 guidance for both adjusted sales and ...